Drugs / VSA006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06322628 | Apr 2024 → Jul 2026 overdue | metabolic dysfunction-associated steatohepatitis | Visirna Therapeutics HK Limited | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-09-26 | Visirna Therapeutics HK Limited | Regulatory Visirna Announces IND Approval from China CDE for VSA006 for Treatment of NASH visirna.com ↗
Visirna announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approved Investigational New Drug (IND) for the initiation of a phase 2 clinical trial of VSA006 for the treatment of adults with non-alcoholic steatohepatitis (NASH) in China. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-04-26 | Visirna Therapeutics HK Limited | Visirna Completes Dosing of the First Patient in China Phase II Study of VSA006 for Treatment of Non-Alcoholic Steatohepatitis (NASH) visirna.com ↗ |
| 2023-09-26 | Visirna Therapeutics HK Limited | Visirna Announces IND Approval from China CDE for VSA006 for Treatment of NASH visirna.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSA006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06322628 ↗ |
| Action | Inhibit | “reduce the protein level of HSD17β13” NCT06322628 ↗ |
| Modality | Small interfering RNA (siRNA) | “VSA006 is a siRNA drug” NCT06322628 ↗ |
| Route | Subcutaneous | “subcutaneous injections” NCT06322628 ↗ |
| Target | HSD17B13 | “targeting HSD17β13 mRNA” NCT06322628 ↗ |